Related Experiment Video
Updated: May 25, 2026
12:00
Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles
Published on: January 22, 2015
Nanoporous multilayer poly(L-glutamic acid)/chitosan microcapsules for drug delivery
Shifeng Yan1, Shuiqin Rao, Jie Zhu
1Department of Polymer Materials, Shanghai University, Shanghai 201800, China.
International Journal of Pharmaceutics
|February 4, 2012
Summary
Novel nanoporous poly(L-glutamic acid)/chitosan microcapsules show promise for drug delivery. These microcapsules effectively load and sustain the release of 5-Fluorouracil, demonstrating significant anticancer activity.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Drug Delivery Systems
Background:
- Developing effective drug delivery systems is crucial for improving therapeutic outcomes.
- Polymeric microcapsules offer potential for controlled drug release and targeted delivery.
- Nanoporous structures can enhance drug loading and release kinetics.
Purpose of the Study:
- To fabricate and characterize novel nanoporous poly(L-glutamic acid)/chitosan (PLGA/CS) multilayer microcapsules.
- To investigate the drug loading capacity and release behavior of these microcapsules using 5-Fluorouracil (5-FU) as a model drug.
- To evaluate the in vitro anticancer activity of the drug-loaded microcapsules.
Main Methods:
- Layer-by-layer (LbL) assembly utilizing porous silica particles as sacrificial templates.
- Characterization using Zeta-potential analyzer, FTIR, TGA, SEM, TEM, and CLSM.
- Drug loading optimization by adjusting parameters like pH and NaCl concentration; in vitro release studies and MTT cytotoxicity assay.
Main Results:
- Successfully fabricated nanoporous PLGA/CS multilayer microcapsules.
- Optimized drug loading content by controlling pH and salt concentration, achieving high loading capacity.
- Demonstrated sustained release of 5-FU, particularly in acidic conditions, with release kinetics fitting Korsmeyer-Peppas and Baker-Lonsdale models.
- Exhibited satisfactory in vitro anticancer activity via MTT assay.
Conclusions:
- Nanoporous PLGA/CS microcapsules are effectively fabricated using LbL assembly.
- These microcapsules provide a promising platform for optimizing drug loading and achieving sustained release of anticancer drugs.
- The developed drug delivery system shows significant potential for cancer therapy applications.
More Related Videos
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...